A Phase II Study of the TRIplet Combination of Dabrafenib, Nivolumab, and Trametinib in Patients With Metastatic Melanoma (TRIDeNT) or Binimetinib, EnCorafenib, and NivolumAb (TRIBECA))
Latest Information Update: 14 Oct 2024
At a glance
- Drugs Binimetinib (Primary) ; Dabrafenib (Primary) ; Encorafenib (Primary) ; Nivolumab (Primary) ; Trametinib (Primary)
- Indications Brain metastases; Malignant melanoma
- Focus Therapeutic Use
- 09 Oct 2024 Planned End Date changed from 8 Dec 2024 to 8 Dec 2025.
- 09 Oct 2024 Planned primary completion date changed from 8 Dec 2024 to 8 Dec 2025.
- 05 Dec 2023 Status changed from suspended to active, no longer recruiting.